The early history of extracorporeal membrane oxygenation "There is a dual purpose in developing a mechanical heart and lung apparatus. The first is to maintain a part of the cardiorespiratory functions temporarily in patients with a failing heart or lung, or both, in the hope that, with such direct aid for a short time, these organs may be able to resume their entire function. The second purpose is of surgical interest."
Bernard J. Miller, John H. Gibbon Jr and Mary H. Gibbon, 1951 1 . While the early pioneers of cardiopulmonary bypass (CPB) hoped the technology could be used as a form of temporary life support for patients with acute cardiac or respiratory failure, initial attempts at prolonged "partial perfusion", using rotating disc oxygenators (in which blood was directly exposed to oxygen) proved disappointing [2] [3] [4] . These "direct contact" oxygenators caused considerable trauma to the blood, resulting in haemolysis and protein denaturation, and could rarely be used for more than a few hours before serious complications occurred 5 .
During the mid-1950s, George Clowes Jr and colleagues from the Department of Cardiothoracic Surgery, Cleveland City Hospital, began to develop a new type of oxygenator to overcome these difficulties. Reflecting on the structure of mammalian lungs, and fish gills, it occurred to them "that membranes ought to play a part in the thing, separating the blood from either gas or gas containing liquid" 6 . Clowes began by assessing the diffusion of oxygen and carbon dioxide across a range of thin plastic films 6, 7 . Ethylcellulose appeared to be the most promising material on the basis of its gas permeability, but proved difficult to use in practice, being brittle, and subject to the formation of pinholes 7, 8 . Polyethylene films (0.02-0.025 mm thick) were more robust, and subsequently utilised in the construction of an experimental membrane oxygenator, in which blood flowed through short narrow channels between layers of polyethylene stacked on top of one another 8 .
Around the same time in the nearby Cleveland Clinic, a team led by Willem Kolff modified a recently designed disposable haemodialyser to create an "artificial coil lung" 9, 10 . The idea behind this was not new. More than a decade earlier, Kolff had been involved in the development of the first effective "artificial kidney" 11 . This comprised 30 metres of cellophane tubing wound around a rotating aluminium cylinder, suspended over a tank of dialysis fluid. As the drum was rotated and blood within the cellophane tubing came into contact with aerated dialysate, Kolff observed that "oxygen is resorbed very rapidly: already after a few windings one sees the blue blood get red" 11 .
Both prototype membrane oxygenators were subject to extensive testing on animals [7] [8] [9] [10] , and by 1957, had been trialled in the CPB circuits of adults and children undergoing open-heart procedures in Ohio 8, 12 . In addition, Clowes attempted the prolonged perfusion of two adults who could not be revived from cardiac arrest. The first patient received central venoarterial (VA) extracorporeal membrane oxygenation (ECMO) for a total of 63 minutes and "resumed a normal heartbeat, but ultimately died from cerebral damage incurred as a result of the arrest" 8 . The second underwent 98 minutes of perfusion, but failed to regain a spontaneous cardiac output 8 .
Subsequent advances in bioengineering, including the development of dimethylpolysiloxane (silicone rubber) membranes 13 , facilitated the development of oxygenators that could be used for days, rather than hours [14] [15] [16] [17] . During the mid-late 1960s, Theodor Kolobow and Warren Zapol, from the National Heart Institute (later the National Heart, Lung, and Blood Institute), Bethesda, demonstrated prolonged survival of full-term lambs exposed to one week of venovenous (VV) ECMO 17 , and the successful employment of ECMO and parenteral nutrition to provide 55 hours of total extrauterine support to a premature lamb fetus suspended in a bath of synthetic amniotic fluid 18 .
Concomitantly, doctors at the Pacific Medical Center, San Francisco, began using a Bramson membrane 14 heart-lung machine to provide partial VA and VV ECMO to adults with cardiogenic shock 19 , or hypoxic respiratory failure refractory Cover photo: Theodor Kolobow (left) and Warren Zapol (right), from the National Heart Institute (later the National Heart, Lung, and Blood Institute), Bethesda, monitoring a fetal lamb supported by extracorporeal membrane oxygenation, c. 1969. Image courtesy of Warren Zapol. to mechanical ventilation with 100% oxygen 19, 20 . The individuals treated were universally moribund at the initiation of extracorporeal therapy, and between 1966 and 1970, there were no long-term survivors.
In 1971, a 24-year old man was admitted to Santa Barbara Cottage Hospital with subadventitial transection of his thoracic aorta, as well multiple pelvic and lower limb fractures, after being struck by a motor vehicle 21 . The patient was intubated, and the aortic injury repaired through a left thoracotomy. Both legs were placed in traction. Four days later he developed worsening acute respiratory distress syndrome (ARDS), and a team from the Pacific Medical Center was flown down to assess his suitability for ECMO. On the morning of the sixth postoperative day "it was the consensus of the attending physicians and surgeons that conventional therapy had been exhausted and that the patient was dying" 21 . Peripheral VA ECMO was initiated using a Bramson membrane heart-lung machine and continued for a total of 75 hours. The patient was subsequently weaned off mechanical ventilation, and eight weeks after admission, transferred to an orthopaedic rehabilitation unit.
The following year at the University of California, Irvine, CA, Robert Bartlett and Alan Gazzaniga utilised partial VA ECMO to support a two-year-old boy with cardiogenic shock following a Mustard procedure for transposition of the great vessels 22 . Three years later, the child was reported to be well, "with no cardiac, neurologic, or renal problems" 23 .
Bartlett and Gazzaniga were also responsible for the first successful use of ECMO for neonatal respiratory failure, which was undertaken in 1975 23 . By the end of the decade, survival among newborns receiving extracorporeal therapy for refractory meconium aspiration syndrome, infant respiratory distress syndrome and persistent fetal circulation approached 50% 24 , and ECMO became an accepted therapy in this patient group.
1979 saw the publication of a multicentre randomised controlled trial comparing conventional mechanical ventilation plus partial VA ECMO, to conventional mechanical ventilation alone, in patients aged 12-65 years, with severe acute respiratory failure 25 . Survival rates were poor in both groups (9.5% and 8.3% respectively). As a result, interest in ECMO for adult respiratory failure diminished, and it would be almost a decade before significant research resumed 26 
